T77714 |
HBV-IN-37
|
|
HBV
|
|
HBV-IN-37 is an HBV inhibitor with an EC50 value of 10 μM and is a candidate compound for the treatment of hepatitis B. ... |
T36747 |
HBV-IN-4
|
|
|
|
HBV-IN-4, a phthalazinone derivative, is a potent and orally active HBV DNA replication inhibitor with an IC50 of 14 nM.... |
T62579 |
HBV-IN-19
|
|
|
|
HBV-IN19 has inhibitory effects on hepatitis B virus (HBV) infection. HBV-IN19 inhibits HBsAg secretion and/or productio... |
T63162 |
HBV-IN-22
|
|
|
|
HBV-IN-22 (Compound LC5f) is an HBV DNA replication inhibitor that acts on both wild-type HBV (IC50: 0.71 μM) and drug-r... |
T73282 |
HBV-IN-31
|
|
|
|
HBV-IN-31 is a potent cccDNA (covalently closed circular DNA) inhibitor. HBV-IN-31 shows anti-HBV activity with an IC 50... |
T73283 |
HBV-IN-32
|
|
|
|
HBV-IN-32 is a potent cccDNA (covalently closed circular DNA) inhibitor. HBV-IN-32 shows anti-HBV activity with an IC 50... |
T62115 |
HBV-IN-24
|
|
|
|
HBV-IN-24 (compound (2 S, 6S)-1a) is a potent inhibitor of HBV. HBV-IN-24 is a strong inhibitor of HBV DNA (EC50: 0.6 nM... |
T62467 |
HBV-IN-18
|
|
|
|
HBV-IN-18 (Compound 3) is an HBV capsid assembly modulator (CpAM) (EC50: 2790 nM). |
T62704 |
HBV-IN-23
|
|
|
|
HBV-IN-23 (Compound 5k) is an inhibitor of HBV DNA replication (IC50: 0.58 μM). HBV-IN-23 inhibits drug-sensitive and dr... |
T64260 |
HBV-IN-20
|
|
|
|
HBV-IN-20 is a potent, orally active HBV inhibitor (EC50: 0.46 μM). HBV-IN-20 is a classical type II CpAM (core protein ... |
T62466 |
HBV-IN-17
|
|
|
|
HBV-IN-17 (compound 8) is a potent regulator of HBV capsid assembly (EC50: 511 nM). |
T62247 |
HBV-IN-9
|
|
|
|
HBV-IN-9 (example 20) is a potent inhibitor of HBsAg (HBV surface antigen) with an IC50 value of 10 nM. HBV-IN-9 (exampl... |
T63079 |
HBV-IN-7
|
|
|
|
HBV-IN-6 is a potent inhibitor of HBV (EC50: 5 nM), taken from patent WO2021213445A1, compound 7. |
T63795 |
HBV-IN-6
|
|
|
|
HBV-IN-6 is a potent inhibitor of HBV (EC50: 44 nM), information from patent WO2021213445A1, compound 3. |
T63852 |
HBV-IN-8
|
|
|
|
HBV-IN-6 is a potent inhibitor of HBV (EC50: 287.9 nM), information from patent WO2021213445A1, compound 13. |
T61558 |
HBV-IN-21
|
|
|
|
HBV-IN-21 (Compound II-8b) is a potent inhibitor of HBV DNA replication, exhibiting an IC50 of 2.2 μM. It demonstrates a... |
T73249 |
HBV-IN-15
|
|
|
|
HBV-IN-15 is a potent inhibitor of covalently closed circular DNA ( cccDNA ). cccDNA serves as the template for viral RN... |
T62626 |
HBV-IN-12
|
|
|
|
HBV-IN-12 is a potent inhibitor of hepatitis B surface antigen (HBsAg) (0.001 μM < EC50 ≤ 0.05 μM). HBV-IN-12 is anti-HB... |
T61115 |
HBV-IN-25
|
|
|
|
HBV-IN-25 is a novel chemical compound that acts as a potent HBV cccDNA reducer when administered orally. It exhibits si... |
T73280 |
HBV-IN-29
|
|
|
|
HBV-IN-29 (ex8), a flavone derivative, is a potent covalently closed circular DNA (cccDNA) inhibitor. cccDNA serves as t... |